So much cost, such little progress

摘要

Urothelial bladder cancer (UBC) is burdensome for patients and expensive for health care providers [1]. Outcomes have changed little for three decades, despite significant improvements in 5-yr survival rates for prostate and kidney cancers during this period [1].